Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,297 papers from all fields of science
Search
Sign In
Create Free Account
Primary sclerosing cholangitis
Known as:
PSC
, Sclerosing Cholangitis
, cholangitis primary sclerosing
Expand
A chronic, autoimmune inflammatory liver disorder characterized by narrowing and scarring of the lumen of the bile ducts. It is often seen in…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
8 relations
Bile duct structure
Biliary tract structure
Cholangitis, Sclerosing
Gastrointestinal system
Expand
Broader (2)
Biliary Tract Diseases
Stenosing cholangitis
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2011
Review
2011
Expandable metal stents for benign biliary disease.
M. Bakhru
,
M. Kahaleh
Gastrointestinal Endoscopy Clinics of North…
2011
Corpus ID: 8789328
Highly Cited
2001
Highly Cited
2001
A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.
R. Advani
,
G. Fisher
,
+4 authors
B. Sikic
Clinical Cancer Research
2001
Corpus ID: 8909742
PURPOSE P-glycoprotein is an efflux pump for many drugs including doxorubicin and paclitaxel. This study evaluated the…
Expand
Highly Cited
2001
Highly Cited
2001
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
R. Dorr
,
C. Karanes
,
+10 authors
A. List
Journal of Clinical Oncology
2001
Corpus ID: 36750865
PURPOSE To determine the maximum-tolerated dose, pharmacokinetic interaction, and activity of PSC 833 compared with daunorubicin…
Expand
2001
2001
Hepatobiliary and extra-hepatic malignancies in primary sclerosing cholangitis.
A. Bergquist
,
U. Broomé
Best practice & research. Clinical…
2001
Corpus ID: 6982348
The increased risk for cholangiocarcinoma in primary sclerosing cholangitis (PSC) is well established, but the factors…
Expand
Review
2001
Review
2001
Primary sclerosing cholangitis
Young-Mee Lee
,
David J. Kim
New England Journal of Medicine
2001
Corpus ID: 29148508
Opinion statementThere is no proven medical therapy for primary sclerosing cholangitis. The goal of management should be…
Expand
Review
2001
Review
2001
Natural history and prognostic models in primary sclerosing cholangitis.
J. Talwalkar
,
K. Lindor
Best practice & research. Clinical…
2001
Corpus ID: 9329265
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease characterized by inflammation and fibrosis of the…
Expand
Highly Cited
1997
Highly Cited
1997
Structure and chromosomal assignment of the human cathepsin K gene.
B. Gelb
,
G. Shi
,
+4 authors
H. Chapman
Genomics
1997
Corpus ID: 20209559
Cathepsin K is a recently identified lysosomal cysteine proteinase that is the major protease responsible for bone resorption and…
Expand
Highly Cited
1996
Highly Cited
1996
p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis.
P. Rizzi
,
S. Ryder
,
B. Portmann
,
J. Ramage
,
N. Naoumov
,
Roger Williams
Gut
1996
Corpus ID: 16309261
The protein encoded by the p53 tumour suppressor gene plays an important part in the regulation of cell growth. Abnormalities of…
Expand
Highly Cited
1982
Highly Cited
1982
Primary Sclerosing Cholangitis: Results of an Aggressive Surgical Approach
H. Pitt
,
H. Thompson
,
R. Tompkins
,
W. Longmire
Annals of Surgery
1982
Corpus ID: 32795605
Traditional management of patients with primary sclerosing cholangitis (PSC) has included steroids and/or choledochotomy plus…
Expand
Review
1982
Review
1982
Primary Sclerosing Cholangitis: A Heterogenous Disease
H. Thompson
,
H. Pitt
,
R. Tompkins
,
W. Longmire
Annals of Surgery
1982
Corpus ID: 24806514
The clinical, radiologic and pathologic features of 37 patients diagnosed as having primary sclerosing cholangitis (PSC) were…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE